Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31652762 | 1.00 | LMNA (0.53) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18948282 | 1.00 | LMNA (0.53) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18948182 | 1.00 | LMNA (0.53) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL6390259 | 0.89 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14946264 | 0.89 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL25400704 | 0.89 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL24831437 | 0.89 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL562388 | 0.89 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL562387 | 0.89 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14816680 | 0.89 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-7935681-B2 | Antiviral nucleosides | MEDIVIR AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-20110015148-A1 | ANTIVIRAL NUCLEOSIDES | MEDIVIR AB (SE) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885THRB 2420/4885MTOR 2137/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885THRB 2420/4885MTOR 2137/4885 |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | L3MBTL1, TDP1, TRDMT1 | LMNA 71/4885THRB 1046/4885MTOR 2237/4885 |
| US-20110015148-A1 | ANTIVIRAL NUCLEOSIDES | PNP, MTAP, UMPS | LMNA 3285/4885THRB 4217/4885MTOR 663/4885 |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | LMNA 1053/4885THRB 4505/4885MTOR 3967/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885THRB 2420/4885MTOR 2137/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | LMNA 2032/4885THRB 2420/4885MTOR 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.